Carl Zeiss Meditec AG ( ETR:AFX ) shareholders should be happy to see the share price up 21% in the last month.

Favorable industrywide trends, such as the aging population, an increasing prevalence of myopia, and a growing access to advanced healthcare across the globe, will act as tailwinds for Zeiss.

Goldman Sachs analyst Richard Felton upgraded Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY), a medical technology company with a $5.2 billion market cap, from Sell to Neutral and increased the price ...

Carl Zeiss Meditec AG / Preliminary announcement on the disclosure of financial statements 05.02.2025 / 09:00 CET/CEST Preliminary announcement of the publication of quarterly reports and quarterly ...

Goldman Sachs has upgraded Carl Zeiss Meditec AG (ETR: AFXG) to 'neutral' from its previous 'sell' rating, signaling a shift ...

On Wednesday, Deutsche Bank (ETR:DBKGn)'s analsysts adjusted the price target for Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY), a leading medical technology company, reducing it from EUR 66.00 to ...

In a report released today, Graham Doyle from UBS maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report), with a price target ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...